Your browser doesn't support javascript.
loading
Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study).
Hümmert, Martin W; Stern, Carlotta; Paul, Friedemann; Duchow, Ankelien; Bellmann-Strobl, Judith; Ayzenberg, Ilya; Schwake, Carolin; Kleiter, Ingo; Hellwig, Kerstin; Jarius, Sven; Wildemann, Brigitte; Senel, Makbule; Berthele, Achim; Giglhuber, Katrin; Luessi, Felix; Grothe, Matthias; Klotz, Luisa; Schülke, Rasmus; Gingele, Stefan; Faiss, Jürgen H; Walter, Annette; Warnke, Clemens; Then Bergh, Florian; Aktas, Orhan; Ringelstein, Marius; Stellmann, Jan-Patrick; Häußler, Vivien; Havla, Joachim; Pellkofer, Hannah; Kümpfel, Tania; Kopp, Bruno; Trebst, Corinna.
Afiliación
  • Hümmert MW; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Stern C; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Paul F; NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, and Max Delbrück Center for Molecular Medicine, Berlin, Germany/Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin,
  • Duchow A; NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, and Max Delbrück Center for Molecular Medicine, Berlin, Germany/Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin,
  • Bellmann-Strobl J; NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, and Max Delbrück Center for Molecular Medicine, Berlin, Germany/Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin,
  • Ayzenberg I; Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
  • Schwake C; Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
  • Kleiter I; Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany/Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany.
  • Hellwig K; Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
  • Jarius S; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
  • Wildemann B; Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
  • Senel M; Department of Neurology, University of Ulm, Ulm, Germany.
  • Berthele A; Department of Neurology, School of Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
  • Giglhuber K; Department of Neurology, School of Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.
  • Luessi F; Department of Neurology, University Medical Center, Johannes Gutenberg University of Mainz, Mainz, Germany.
  • Grothe M; Department of Neurology, University Medicine of Greifswald, Greifswald, Germany.
  • Klotz L; Department of Neurology, University of Münster, Münster, Germany.
  • Schülke R; Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.
  • Gingele S; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Faiss JH; Department of Neurology, Asklepios Expert Clinic Teupitz, Teupitz, Germany.
  • Walter A; Department of Neurology, Herford Hospital, Herford, Germany.
  • Warnke C; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Then Bergh F; Department of Neurology, University of Leipzig, Leipzig, Germany.
  • Aktas O; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Ringelstein M; Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany/Department of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Stellmann JP; Department of Neurology and Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany/Aix-Marseille Univ, CNRS, CRMBM, UMR 7339, Marseille, France/APHM, Hopital de la Timone, CEMEREM, Marseille, France.
  • Häußler V; Department of Neurology and Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Havla J; Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität München, Munich, Germany/Data Integration for Future Medicine Consortium, LMU Hospital, Ludwig-Maximilians Universität München, Munich, Germany.
  • Pellkofer H; Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Kümpfel T; Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Kopp B; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Trebst C; Department of Neurology, Hannover Medical School, Hannover, Germany.
Mult Scler ; 29(7): 819-831, 2023 Jun.
Article en En | MEDLINE | ID: mdl-36786424
ABSTRACT

BACKGROUND:

There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD).

OBJECTIVE:

To assess cognitive performance and changes over time in NMOSD.

METHODS:

This study included data from 217 aquaporin-4-IgG-seropositive (80%) and double-seronegative NMOSD patients. Cognitive functions measured by Symbol Digit Modalities Test (SDMT), Paced Auditory Serial-Addition Task (PASAT), and/or Multiple Sclerosis Inventory Cognition (MuSIC) were standardized against normative data (N = 157). Intraindividual cognitive performance at 1- and 2-year follow-up was analyzed. Cognitive test scores were correlated with demographic and clinical variables and assessed with a multiple linear regression model.

RESULTS:

NMOSD patients were impaired in SDMT (p = 0.007), MuSIC semantic fluency (p < 0.001), and MuSIC congruent speed (p < 0.001). No significant cognitive deterioration was found at follow-up. SDMT scores were related to motor and visual disability (pBon < 0.05). No differences were found between aquaporin-4-IgG-seropositive and double-seronegative NMOSD.

CONCLUSIONS:

A subset of NMOSD patients shows impairment in visual processing speed and in semantic fluency regardless of serostatus, without noticeable changes during a 2-year observation period. Neuropsychological measurements should be adapted to physical and visual disabilities.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neuromielitis Óptica / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neuromielitis Óptica / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania
...